Operation Warp Speed: implications for global vaccine security.
Lancet Glob Health
; 9(7): e1017-e1021, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-1294377
ABSTRACT
Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Global Health
/
Drug Development
/
COVID-19 Vaccines
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Lancet Glob Health
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS